Loading clinical trials...
Loading clinical trials...
Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (CEDAR Study)
This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.
Age
50 - No limit years
Sex
ALL
Healthy Volunteers
No
Retinal Research Institute, LLC
Phoenix, Arizona, United States
Associated Retina Consultants, Ltd.
Phoenix, Arizona, United States
Arizona Retina and Vitreous Consultants
Phoenix, Arizona, United States
Retina Associates Southwest, P.C.
Tucson, Arizona, United States
The Retina Partners
Encino, California, United States
Retina Consultants of Orange County
Fullerton, California, United States
Mark B. Kislinger MD Inc.
Glendora, California, United States
Atlantis Retina Institute (Atlantis Eyecare)
Huntington Beach, California, United States
Loma Linda University Medical Center
Loma Linda, California, United States
Northern California Retina Vitreous Associates Medical Group, INC.
Mountain View, California, United States
Start Date
June 25, 2015
Primary Completion Date
April 18, 2018
Completion Date
June 19, 2019
Last Updated
July 28, 2020
939
ACTUAL participants
Abicipar Pegol
DRUG
Ranibizumab
DRUG
Sham Procedure
OTHER
Lead Sponsor
Allergan
NCT05913063
NCT07446582
NCT06779773
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions